|
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha (registration) The three highest doses of dupilumab in combination with standard-of-care therapy met the primary endpoint of a statistically significant improvement from baseline in forced expiratory volume over one second (FEV1) at week 12 in patients with high … |
View full post on asthma – Google News